Literature DB >> 9351479

The Parkinson's Disease Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score.

C Jenkinson1, R Fitzpatrick, V Peto, R Greenhall, N Hyman.   

Abstract

OBJECTIVES: to briefly outline the development and validation of the Parkinson's Disease Questionnaire (PDQ-39) and then to provide evidence for the use of the measure as either a profile of health status scores or a single index figure.
DESIGN: the PDQ-39 was administered in two surveys: a postal survey of patients registered with local branches of the Parkinson's Disease Society of Great Britain (n = 405) and a survey of patients attending neurology clinics for treatment for Parkinson's disease (n = 146). Data from the eight dimensions of the PDQ-39 were factor-analysed. This produced a single factor on the data from both surveys. OUTCOME MEASURES: the eight dimensions of the PDQ-39 and the new single index score-the Parkinson's disease summary index (PDSI), together with clinical assessments (the Columbia rating scale and the Hoehn and Yahr staging score).
RESULTS: in the postal survey 227 patients returned questionnaires (58.2%). AH 146 patients approached in the clinic sample agreed to take part. Higher-order principal-components factor analysis was undertaken on the eight dimensions of the PDQ-39 and produced one factor on both datasets. Consequently it was decided that the scores of the eight domains could be summed to produce a single index figure. The psychometric properties of this index were explored using reliability tests and tests of construct validity. The newly derived single index was found to be both internally reliable and valid. DISCUSSION: data from the PDQ-39 can be presented either in profile form or as a single index figure. The profile should be of value in studies aimed at determining the impact of treatment regimes upon particular aspects of functioning and well-being in patients with Parkinson's disease, while the PDSI will provide a summary score of the impact of the illness on functioning and well-being and will be of use in the evaluation of the overall effect of different treatments. Furthermore, the PDSI reduces the number of statistical comparisons and hence the role of chance when exploring data from the PDQ-39.

Entities:  

Mesh:

Year:  1997        PMID: 9351479     DOI: 10.1093/ageing/26.5.353

Source DB:  PubMed          Journal:  Age Ageing        ISSN: 0002-0729            Impact factor:   10.668


  315 in total

1.  Health related quality of life in Parkinson's disease: a systematic review of disease specific instruments.

Authors:  J Marinus; C Ramaker; J J van Hilten; A M Stiggelbout
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-02       Impact factor: 10.154

Review 2.  Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias.

Authors:  R C Dodel; K Berger; W H Oertel
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

3.  Latent growth-curve analysis reveals that worsening Parkinson's disease quality of life is driven by depression.

Authors:  Jacob D Jones; Michael Marsiske; Michael S Okun; Dawn Bowers
Journal:  Neuropsychology       Date:  2014-11-03       Impact factor: 3.295

4.  Treadmill training for individuals with Parkinson disease.

Authors:  Gammon M Earhart; April J Williams
Journal:  Phys Ther       Date:  2012-04-26

5.  Validation of a home environment test battery for supporting assessments in advanced Parkinson's disease.

Authors:  Jerker Westin; Mauro Schiavella; Mevludin Memedi; Dag Nyholm; Mark Dougherty; Angelo Antonini
Journal:  Neurol Sci       Date:  2011-11-09       Impact factor: 3.307

6.  Beyond Mere Symptom Relief in Deep Brain Stimulation: An Ethical Obligation for Multi-faceted Assessment of Outcome.

Authors:  C S Kubu; P J Ford
Journal:  AJOB Neurosci       Date:  2012-01-05

7.  The 39-Item Parkinson's Disease Questionnaire (PDQ-39): Is it a Unidimensional Construct?

Authors:  Peter Hagell; Maria H Nilsson
Journal:  Ther Adv Neurol Disord       Date:  2009-07       Impact factor: 6.570

8.  Long-term duodenal levodopa infusion in Parkinson's disease: a 3-year motor and cognitive follow-up study.

Authors:  Maurizio Zibetti; Aristide Merola; Valeria Ricchi; Alice Marchisio; Carlo Alberto Artusi; Laura Rizzi; Elisa Montanaro; Dario Reggio; Claudio De Angelis; Mario Rizzone; Leonardo Lopiano
Journal:  J Neurol       Date:  2012-07-08       Impact factor: 4.849

9.  Health-related quality of life in Parkinson's: impact of 'off' time and stated treatment preferences.

Authors:  Cicely Kerr; Emily J Lloyd; Charlotte E Kosmas; Helen T Smith; James A Cooper; Karissa Johnston; Emma McIntosh; Andrew J Lloyd
Journal:  Qual Life Res       Date:  2015-12-01       Impact factor: 4.147

10.  Neurofunctional correlates of attention rehabilitation in Parkinson's disease: an explorative study.

Authors:  Antonio Cerasa; Maria Cecilia Gioia; Maria Salsone; Giulia Donzuso; Carmelina Chiriaco; Sabrina Realmuto; Alessandra Nicoletti; Gabriele Bellavia; Aurelia Banco; Marco D'amelio; Mario Zappia; Aldo Quattrone
Journal:  Neurol Sci       Date:  2014-02-20       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.